Metamizole

Jump to: navigation, search
Metamizole.png
Metamizole
Systematic (IUPAC) name
Sodium [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-
1H-pyrazol-4-yl)methylamino] methanesulfonate
Identifiers
CAS number 68-89-3
ATC code N02BB02
PubChem 80254
Chemical data
Formula C13H16N3NaO4S 
Mol. mass 311.358 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

WikiDoc Resources for

Metamizole

Articles

Most recent articles on Metamizole

Most cited articles on Metamizole

Review articles on Metamizole

Articles on Metamizole in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Metamizole

Images of Metamizole

Photos of Metamizole

Podcasts & MP3s on Metamizole

Videos on Metamizole

Evidence Based Medicine

Cochrane Collaboration on Metamizole

Bandolier on Metamizole

TRIP on Metamizole

Clinical Trials

Ongoing Trials on Metamizole at Clinical Trials.gov

Trial results on Metamizole

Clinical Trials on Metamizole at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Metamizole

NICE Guidance on Metamizole

NHS PRODIGY Guidance

FDA on Metamizole

CDC on Metamizole

Books

Books on Metamizole

News

Metamizole in the news

Be alerted to news on Metamizole

News trends on Metamizole

Commentary

Blogs on Metamizole

Definitions

Definitions of Metamizole

Patient Resources / Community

Patient resources on Metamizole

Discussion groups on Metamizole

Patient Handouts on Metamizole

Directions to Hospitals Treating Metamizole

Risk calculators and risk factors for Metamizole

Healthcare Provider Resources

Symptoms of Metamizole

Causes & Risk Factors for Metamizole

Diagnostic studies for Metamizole

Treatment of Metamizole

Continuing Medical Education (CME)

CME Programs on Metamizole

International

Metamizole en Espanol

Metamizole en Francais

Business

Metamizole in the Marketplace

Patents on Metamizole

Experimental / Informatics

List of terms related to Metamizole


Metamizole sodium is a non-steroidal anti-inflammatory drug (NSAID), commonly used in the past as a powerful painkiller and fever reducer. It is better known under the names Dipyrone, Analgin and Novalgin.

Metamizole was first synthesized by the German company Hoechst AG in 1920, and its mass production started in 1922. It remained freely available worldwide until the 1970s, when it was discovered that the drug carries a small risk of causing agranulocytosis - a very dangerous and potentially fatal condition. Controversy remains regarding the level of risk. Several national medical authorities have banned metamizole either totally or have restricted it to be available only on prescription.

Risks of agranulocytosis

According to comments by Dr Anthony Wong of the University of São Paulo, Brazil in a WHO newsletter,[1] recent studies estimate that the incidence rate of metamizole-induced agranulocytosis is between 0.2 and 2 cases per million person days of use, with approximately 7% of all cases fatal (provided that all patients have access to urgent medical care). In other words, one should expect 50 to 500 deaths annually due to metamizole in a country of 300 million, assuming that every citizen takes the drug once a month. This is not a very high rate compared to other drugs - for example, the prescription drug clozapine is known to be at least 50 times more likely to trigger agranulocytosis. However, at the time the risk was assumed to be much greater and, as such, excessive for an over-the-counter analgesic, especially considering the existence of safer alternatives (aspirin and ibuprofen).

A study in Northern Sweden published in 2002 estimated the total risk during metamizole therapy for patients in hospitals (inpatients) and outside of hospital (outpatients) about 3 to 100 times greater than that estimated by Dr Wong: "Given certain assumptions including the actual amounts prescribed the calculated risks of agranulocytosis would be approximately one out of every 31,000 metamizole-treated inpatients and one of every 1400 metamizole-treated outpatients."[2]

Availability around the world

Metamizole was banned in Sweden in 1974, in the United States in 1977; more than 30 countries, including Japan, Australia, Iran, and part of the European Union, have followed suit. In these countries metamizole is still occasionally used as a veterinary drug. In Germany it became a prescription drug. Some European pharmaceutical companies, notably Hoechst and Merck, continue to develop metamizole-containing drugs and market them in some countries. In Sweden, the ban was lifted in 1995 and re-introduced in 1999 only to be taken off the market again just a few years later.

In other parts of the world (notably in Spain, Mexico, India, Brazil, Russia, Bulgaria, Romania, Israel and Third World countries) metamizole is still freely available over-the-counter, remains one of the most popular analgesics, and plays an important role in self-medication. For example, metamizole and metamizole-containing drugs account for 80% of OTC analgesic market in Russia, whereas ibuprofen accounts for 2.5%. In Brazil, metamizole (Novalgina) products, although over-the-counter, carry warnings to avoid usage by those under 19 years old, and have several informations about early detection and treatment of agranulocytosis. Although the Brazilian government did not push for a ban on the drug, its use has seen a decline on the past years as pharmaceutical companies and doctors pushed aspirin, paracetamol and ibuprofen based products as replacement, specialy regarding child care. Amongst adults it is still widely used. Some of the most widely available metamizole-containing product still in use in Brazil are: Buscopan Plus (under the name of Buscopan Composto), Novalgina and Neosaldina. Generic Dipyrone is also available.

Media attention

Metamizole received brief period of attention by American media in 2001[3], when a Latino immigrant boy was admitted into a Salt Lake City clinic with symptoms of agranulocytosis. It was discovered that the drug remained freely available in Latino shops and highly popular among Mexican immigrants, despite the ban. The ongoing "LATIN" Study, a multicenter international case-control study, is examining the incidence of agranulocytosis in Latin America and the role of metamizole.

Brand names

  • Brazil: Novalgina, Neosaldina, Sedalgina, Doridina, Migranette, Benegrip, Anador, Magnopyrol, Conmel, Difebril, Termopirona, Dipifarma, Termosil, Dorona, Hynalgin, Lisador, among others.
  • Bulgaria: Proalgin, Analgin
  • Croatia: Analgin
  • Finland: Litalgin
  • Germany: Novalgin, Analgin, Berlosin, Metalgin, Metamizol-Puren, Novaminsulfon.
  • Hungary: Algopyrin
  • India: Novalgin
  • Israel: Optalgin
  • Italy: Novalgina
  • Macedonia: Analgin
  • Mexico: Neo-Melubrina
  • Poland: Pyralgina
  • Romania: Algocalmin, Novocalmin, Algozone, Nevralgin
  • Russia/Bulgaria: Tempalgin (combination drug; metamizole is one of its components)
  • Slovenia: Analgin
  • Serbia: Analgin
  • Spain: Nolotil
  • Switzerland: Novalgin
  • Turkey: Novalgin
  • Venezuela: Novalcina

References


bg:Норамидопирин de:Metamizol he:דיפירון hu:Metamizol-nátrium


Linked-in.jpg